Senolytics + Metformin: AMPK Activation and Senescent Cell Clearance

Expert Summary

Metformin (the diabetes drug being evaluated for longevity in the TAME trial) activates AMPK and reduces mTOR activity, slowing processes that drive cellular senescence. Senolytics eliminate senescent cells that have already formed. The combination is theoretically synergistic: metformin reduces senescence induction rate; senolytics clear existing burden.

Key Facts

• Metformin AMPK mechanism: Metformin inhibits Complex I of the mitochondrial electron transport chain, increasing AMP:ATP ratio and activating AMPK. AMPK inhibits mTOR and activates autophagy, reducing senescence-driving processes.
• SASP suppression: Metformin reduces NF-κB-dependent SASP expression in existing senescent cells, making them less toxic without eliminating them. Senolytics eliminate them entirely — a stronger intervention.
• TAME trial: The TAME (Targeting Aging with Metformin) trial is the first longevity RCT tracking aging-related outcomes in older adults (n=3,000). Results expected ~2027. This is the largest human longevity drug trial to date.
• Interaction check: Metformin and quercetin share some OCT2 transporter competition. High-dose quercetin (>1,000 mg) may modestly increase metformin blood levels. At typical supplement doses, this interaction is clinically negligible.
• Access: Metformin requires a prescription (type 2 diabetes treatment; used off-label for longevity at 500–1,000 mg/day). Natural AMPK activators (berberine, quercetin, exercise) provide partial overlapping effects without prescription.

Recommended Products

Frequently Asked Questions

Can metformin and quercetin be taken together?

At standard supplement doses of quercetin (200–500 mg/day), the OCT2 transporter competition with metformin is minimal. Inform your prescribing physician regardless. High-dose quercetin (1,000 mg) on senolytic burst days with metformin warrants physician awareness.

Is berberine a natural metformin substitute?

Berberine activates AMPK via the same indirect mechanism as metformin (mitochondrial complex I inhibition) and shows comparable glycemic effects in some trials. It is OTC and may substitute for metformin in the AMPK pathway component of this stack.

Scientific References

• Barzilai N et al. Metformin as a tool to target aging. Cell Metabolism. 2016. PMID: 27304505
• Kirkland JL et al. The clinical potential of senolytic drugs. Journal of the American Geriatrics Society. 2017. PMID: 28869295